000			03256nam a22004217a 4500
008			240807s20222022 xxu||||| |||| 00| 0 eng d
022			_a2218-6778
024			_aPMC11093044 [pmc]
024			_atbcr-03-29 [pii]
040			_aOvid MEDLINE(R)
099			_a38751542
245			_aReduction in tumor grade and Ki-67 in postmenopausal patient with node-positive invasive ductal carcinoma following combination hormone replacement therapy cessation: a case report.
251			_aTranslational Breast Cancer Research : A Journal Focusing on Translational Research in Breast Cancer. 3:29, 2022.
252			_aTransl Breast Cancer Res. 3:29, 2022.
253			_aTranslational breast cancer research : a journal focusing on translational research in breast cancer
260			_c2022
260			_p2022
265			_sepublish
265			_tPubMed-not-MEDLINE
266			_d2024-08-07
266			_z2024/05/16 03:36
520			_aBackground: While praised for its benefits in treating symptoms related to menopausal changes, hormone replacement therapy (HRT) has been associated with an increased risk for hormone-dependent cancer development, particularly endometrial and breast. Few studies have elucidated the relationship between HRT cessation and hormone receptor-positive breast cancer proliferation. We report herein, to the best of our knowledge, the first case of 28.6% relative reduction in proliferation index marker Ki-67 in node-positive hormone receptor-positive breast cancer following HRT cessation.
520			_aCase Description: We report an unusual case of a 64-year-old female patient with longstanding HRT for fifteen years who underwent immediate discontinuation after diagnosis of poorly differentiated invasive ductal carcinoma. We observed a reduction in tumor grade from poorly differentiated at time of biopsy to moderately differentiated at time of surgery following cessation of HRT, as well as a reduction in the tumor proliferation index (Ki-67) from 70% to 50%. The patient has remained recurrence-free at the one-year mark postoperatively with continued follow-up.
520			_aConclusions: This case highlights potential clinical benefits associated with HRT discontinuation in the postmenopausal population with preexisting hormone-dependent cancers with high proliferation index, as well as the usefulness of Ki-67 in measuring response to aromatase inhibition in this subpopulation of patients.
520			_aKeywords: Hormone replacement therapy (HRT); breast cancer; tumor grade; Ki-67; case report. Copyright 2022 Translational Breast Cancer Research. All rights reserved.
546			_aEnglish
650			_zAutomated
651			_aMedStar Washington Hospital Center
656			_aMedStar General Surgery Residency
656			_aMedStar Georgetown University Hospital/MedStar Washington Hospital Center
656			_aSurgery/Plastic Surgery
657			_aCase Reports
700			_aFan, Kenneth L _bMWHC
700			_aMasanam, Monika _bMGUH _cMedStar General Surgery Residency _dMD
790			_aKing CA, Masanam MK, Maini AS, Merritt CM, Fan KL, Greenwalt IT
856			_uhttps://dx.doi.org/10.21037/tbcr-22-26 _zhttps://dx.doi.org/10.21037/tbcr-22-26
942			_cART _dArticle
999			_c14503 _d14503